Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership
|
EQS-News: M1 Kliniken AG
/ Key word(s): Annual Report/Dividend
M1 Kliniken AG: Strong Earnings Growth in 2024 – Strategic Focus on Global Market Leadership Berlin, 21/05/2025 - M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its annual report for the 2024 financial year. The M1 Group continued on its growth trajectory, driven in particular by the high-margin Beauty segment. Looking ahead, the company sees substantial growth potential: revenues in the Beauty segment are expected to reach between EUR 200 and 300 million by 2029, with a targeted EBIT margin of at least 20%. The strategic goal is to establish M1 Med Beauty as the leading global brand for aesthetic treatments. M1 is already the market leader in Europe – offering the highest medical standards at the best price. With the proposed dividend of EUR 0.50 per share, the Management Board and Supervisory Board reaffirm the Group’s dividend policy. Key Financial Highlights 2024
Significant Increase in Profitability and Cash Flow The consolidated net profit after minority interests rose markedly to EUR 16.0 million in 2024 (previous year: EUR 10.3 million). Earnings per share increased accordingly from EUR 0.54 to EUR 0.85. Operating cash flow more than tripled to EUR 30.5 million (previous year: EUR 7.8 million), while free cash flow improved significantly to EUR 24.9 million, compared to EUR -1.5 million in the previous year. The full Annual Report 2024 is available for download at www.m1-kliniken.de. About M1 Kliniken AG M1 Kliniken AG is the leading fully integrated provider of aesthetic medical healthcare services in Europe and Australia. The Group offers products and services of the highest quality standards in the aesthetic and surgical fields. M1 currently offers beauty treatments at 58 clinics under the "M1 Med Beauty" brand. The M1 Schlossklinik for Plastic and Aesthetic Surgery in Berlin is one of the largest and most modern facilities of its kind in Europe, with six operating theaters and 35 beds. M1 has been driving forward its internationalization since the end of 2018 and is currently represented in ten countries. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
21.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2141988 |
| End of News | EQS News Service |
|
|
2141988 21.05.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.